24 jul: Bobler fra dybet fik hammerslag på rekordpriser ved nyligt afhold..
01 aug: Mercedes CLS Shooting Brake på vej til Danmark
26-07-2012 22:51:00

Amgen 2nd-Quarter Profit Rises 8.2%; 2012 Outlook Raised

Relateret indhold

By Tess Stynes

Amgen Inc.'s (AMGN) second-quarter earnings rose 8.2% as weaker sales of the biopharmaceutical company's anemia drugs were offset by growth of other treatments.

Shares rose 4.7% to $83 in after-hours trading Thursday as adjusted earnings and revenue beat expectations and the company raised its 2012 outlook. Through the close, the stock was up about 23% this year.

For the year, the company raised its per-share earnings estimate to a range of $6.20 to $6.35 on revenue of $16.9 billion to $17.2 billion, from its prior estimates for $5.90 to $6.15 and $16.1 billion to $16.5 billion.

Amgen has been pursuing deals to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed a $1.16 billion acquisition of Micromet Inc., a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.27 billion, or $1.61 a share, up from $1.17 billion, or $1.25 a share, a year earlier. Excluding acquisition-related charges, stock-compensation expenses and other items, earnings were up at $1.83 from $1.37.

Revenue increased 13% to $4.48 billion, including 8% growth in product sales.

Analysts polled by Thomson Reuters most recently projected earnings of $1.54 a share on revenue of $4.08 billion.

Combined sales of Neulasta and Neupogen, which are used to ward off infections in patients undergoing cancer treatment, grew 2% mainly on an increase in U.S. average selling prices. Enbrel sales jumped 11%.

However, sales of anti-anemia drugs Aranesp and Epogen were down about 8% and 3%, respectively.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Second-quarter sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, saw sales increase 17% from the first quarter. Sales of Prolia, for osteoporosis in women, climbed 36% quarter to quarter.

Write to Tess Stynes at tess.stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 26, 2012 16:51 ET (20:51 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Danske/CEO: Robust økonomi - men risiko for lille tilbageslag

26-04-2018 09:20:48
Danske Banks administrerende direktør, Thomas Borgen, har et optimistisk syn på den makroøkonomiske udvikling, selv om risikoen for et "lille tilbageslag" er øget hen over de seneste måneder. - Vores vurdering er, at verdensøkonomien ser relativ robust ud, og vi forventer en vækst mellem 3,5 og 3,7 pct. i år. Men der er jo visse tendenser, man skal holde øje med - specielt geopolitiske forhold ell..

Danske Bank/CEO: Resultat viser bredden i bankens forretning

26-04-2018 08:37:10
Danske Banks administrerende direktør, Thomas Borgen, kalder bankens resultater i første kvartal for "gode og stabile" og understøttet af en god underliggende udvikling i de nordiske økonomier. - Resultatet viser bredden i Danske Banks forretning, og der er også en fornuftig udvikling i de nordiske økonomier, som genspejler sig i vores kunders økonomiske ve og vel. Det gør at vi har lave tab og he..

Sydbank/CEO: Har ingen aktuelle planer om at byde på Nordjyske Bank

25-04-2018 10:08:14
Da Nordjyske Bank så sig om efter alternativer, efter at Jyske Bank havde lagt et købstilbud på banken, blev Sydbank fra flere sider udpeget som en mulighed. Og selv om den Aabenraa-baserede bank hele tiden står parat til at agere efter sine egne og interessenternes interesser, så har det ikke været på tale at afgive et købstilbud på Nordjyske Bank.- Vi holder altid øje med, hvad der sker på marke..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Onsdagens aktier: Skuffelse i toppen sendte Nordea og Novozymes i bund
2
Danske Bank Q1: Lidt bedre end ventet - nedskrivninger overrasker
3
Danske Bank får påtale af Finanstilsynet - NY
4
Novo-rival: Oral Semaglutid vil næppe dæmpe vores vækst
5
Bavarian: Amerikanere har mere end tredoblet shortposition i april

Relaterede aktiekurser

Amgen Inc 174,83 1,7% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Cookie- og privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
26. april 2018 14:59:00
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180423.5 - EUROWEB3 - 2018-04-26 14:59:00 - 2018-04-26 14:59:00 - 1 - Website: OKAY